m6A去甲基化酶ALKBH5——新的原癌基因-CSCIED科技核心评价数据库-手机版

m6A去甲基化酶ALKBH5——新的原癌基因

ALKBH5, a kind of m6A demethylase, a new proto-oncogene

ES评分 0 浏览量：54 下载量：0

DOI
刊名	生命的化学
年，卷(期)	2022, 42(09)
作者	袁敏1,2周志刚3杨萍2陈灵瑶1侯琳2翁若兰2涂剑1,
作者单位	1.桂林医学院药学院2.桂林医学院附属医院广西肝脏损伤与修复分子医学重点实验室3.桂林医学院第二附属医院
摘要	AlkB同源蛋白5（AlkB homolog 5,ALKBH5）属于AlkB家族，对N6-甲基腺苷（N6-methyladenosine,m6A）具有高效的脱甲基活性，参与RNA的剪接、加工、出核和翻译等生物学过程。近年来研究发现，ALKBH5在卵巢癌、胃癌、肺癌和胶质母细胞瘤等生殖、消化、呼吸和神经系统恶性肿瘤中的表达异常升高，而且这种异常高表达往往密切关联癌细胞增殖、侵袭/迁移与耐药，预示ALKBH5可能成为一种新的原癌基因。因此，本文主要就ALKBH5在这些系统癌症中的促进作用及其机制作一综述，旨在明确新的癌症防治靶点并研发新药。
Abstract	AlkB homologue 5(ALKBH5), belonging to the AlkB family, has efficient demethylation activity on N6-methyladenosine(m6A) involved in the biological processes such as RNA splicing, processing, nuclear exporting, translating, and etc. Recent studies have found that ALKBH5 expression is abnormally elevated in the cancers from reproductive, digestive, respiratory and nervous systems such as ovarian, gastric, lung cancer,glioblastoma, and so on. Furthermore, the high expression often affects the cell proliferation, invasion/migration of cancer, and closely related with drug resistance. All above, ALKBH5 might become another new proto-oncogene. Therefore, this paper mainly reviews the promoting role and mechanism of ALKBH5 in these systemic cancers, aiming to identify new targets for clinical treatment and prevention of cancer and develop new drugs.
关键词	m6A;去甲基化酶;AlkB同源蛋白5;原癌基因;
KeyWord	m A ;demethylase;AlkB homolog 5;proto-oncogene
基金项目
页码	1722-1728

参考文献
相关文献

[1] Tong J, Flavell RA, Li HB. RNA m6A modification and its function in diseases. Front Med, 2018, 12(4): 481- 489

[2] Yang Y, Hsu PJ, Chen YS, et al. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res, 2018, 28(6): 616- 624

[3] Xu C, Liu K, Tempel W, et al. Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single- stranded N6- methyladenosine RNA demethylation. J Biol Chem, 2014, 289(25): 17299- 17311

[4] Fu Y, Dominissini D, Rechavi G, et al. Gene expression regulation mediated through reversible m6A RNA methylation. Nat Rev Genet, 2014, 15(5): 293- 306

[5] Wang J, Wang J, Gu Q, et al. The biological function of m6A demethylase ALKBH5 and its role in human disease. Cancer Cell Int, 2020, 20(1): 347

[6] Liu S, Li Q, Chen K, et al. The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression. Biomed pharmacother, 2020, 127: 110098

[7] Wang T, Kong S, Tao M, et al. The potential role of RNA N6- methyladenosine in cancer progression. Mol Cancer, 2020, 19(1): 88

[8] Song W, Fei F, Qiao F, et al. ALKBH5- mediated N6-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation. Cell Death Discov, 2022, 8(1): 25

[9] Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti- PD- 1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA, 2020, 117(33): 20159- 20170

[10] Zhu H, Gan X, Jiang X, et al. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR- 7 and Bcl- 2. J Exp Clin Cancer Res, 2019, 38(1): 163

[11] Nie S, Zhang L, Liu J, et al. ALKBH5- HOXA10 loop- mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res, 2021, 40(1): 284

[12] Jiang Y, Wan Y, Gong M, et al. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF- κB pathway. J Cell Mol Med, 2020, 24(11): 6137- 6148

[13] Pu X, Gu Z, Gu Z. ALKBH5 regulates IGF1R expression to promote the proliferation and tumorigenicity of endometrial cancer. J Cancer, 2020, 11(19): 5612- 5622

[14] Xu X, Zhou E, Zheng J, et al. Prognostic and predictive value of m6A "eraser" related gene signature in gastric cancer. Front Oncol, 2021, 11: 631803

[15] Guo T, Liu DF, Peng SH, et al. ALKBH5 promotes colon cancer progression by decreasing methylation of the lncRNA NEAT1. Am J Transl Res, 2020, 12(8): 4542- 4549

[16] Tsuchiya K, Yoshimura K, Iwashita Y, et al. m6A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non- small- cell lung cancer. Cancer Gene Ther, 2022. doi: 10.1038/s41417- 022- 00451- 8

[17] Liu X, Wang Z, Yang Q, et al. RNA Demethylase ALKBH5 prevents lung cancer progression by regulating EMT and stemness via regulating p53. Front Oncol, 2022, 12: 858694

[18] Lathia JD, Mack SC, Mulkearns- Hubert EE, et al. Cancer stem cells in glioblastoma. Genes Dev, 2015, 29(12): 1203- 1217

[19] Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF- dependent and ALKBH5- mediated m6A- demethylation of NANOG mRNA. Proc Natl Acad Sci USA, 2016, 113(14): E2047- E2056

[20] Wang W, Min L, Qiu X, et al. Biological function of long non- coding RNA (lncRNA) xist. Front Cell Dev Biol, 2021, 9: 645647

[21] Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta, 2014, 1839(11): 1097- 1109

[22] Nagaki Y, Motoyama S, Yamaguchi T, et al. m6A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells, 2020, 25(8): 547- 561

[23] Xue J, Xiao P, Yu X, et al. A positive feedback loop between AlkB homolog 5 and miR- 193a- 3p promotes growth and metastasis in esophageal squamous cell carcinoma. Hum Cell, 2021, 34(2): 502- 514

[24] Yeermaike A, Gu P, Liu D, et al. LncRNA NEAT1 sponges miR- 214 to promoted tumor growth in hepatocellular carcinoma. Mamm Genome, 2022, 33(3): 525- 533

[25] Chen F, Li M, Wang L. LncRNA CASC11 promotes hepatocellular carcinoma progression via upregulation of UBE2T in a m6A- dependent manner. Front Oncol, 2021, 11: 772671

[26] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394- 424

[27] Zhu Z, Qian Q, Zhao X, et al. N6- methyladenosine ALKBH5 promotes non- small cell lung cancer progress by regulating TIMP3 stability. Gene, 2020, 731: 144348

[28] Guo J, Wu Y, Du J, et al. Deregulation of UBE2C- mediated autophagy repression aggravates NSCLC progression. Oncogenesis, 2018, 7(6): 49

[29] Yu H, Zhang Z. ALKBH5- mediated m6A demethylation of lncRNA MRMP plays an oncogenic role in lung adenocarcinoma. Mamm Genome, 2021, 32(3): 195- 203

[30] Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol, 2018, 15(7): 422- 442

[31] Kowalski- Chauvel A, Lacore MG, Arnauduc F, et al. The m6A RNA demethylase ALKBH5 promotes radioresistance and invasion capability of glioma stem cells. Cancers, 2020, 13(1): 40

[32] Zhang S, Zhao BS, Zhou A, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem- like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell, 2017, 31(4): 591- 606. e6

[33] Cui Y, Wang Q, Lin J, et al. MiRNA- 193a- 3p regulates the AKT2 pathway to inhibit the growth and promote the apoptosis of glioma cells by targeting ALKBH5. Front Oncol, 2021, 11: 600451

[34] Liu Z, Chen Y, Wang L, et al. ALKBH5 promotes the proliferation of glioma cells via enhancing the mRNA stability of G6PD. Neurochem Res, 2021, 46(11): 3003-3011

[35] Shen C, Sheng Y, Zhu AC, et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell- renewal in acute myeloid leukemia. Cell Stem Cell, 2020, 27(1): 64- 80. e9

[36] Chen S, Zhou L, Wang Y. ALKBH5- mediated m6A demethylation of IncRNA PVT1 plays an oncogenic role in osteosarcoma. Cancer Cell Int, 2020, 20(1): 34

[37] Hao L, Yin J, Yang H, et al. ALKBH5- mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma. Aging, 2021, 13(3): 4045- 4062

[38] Wang S, Sun C, Li J, et al. Roles of RNA methylation by means of N6- methyladenosine (m6A) in human cancers. Cancer Lett, 2017, 408: 112- 120

[39] Giannone G, Attademo L, Scotto G, et al. Endometrial cancer stem cells: role, characterization and therapeutic implications. Cancers, 2019, 11(11): 1820

[40] Keith B, Simon MC. Hypoxia- inducible factors, stem cells, and cancer. Cell, 2007, 129(3): 465- 472

[41] Chen G, Liu B, Yin S, et al. Hypoxia induces an endometrial cancer stem- like cell phenotype via HIF- dependent demethylation of SOX2 mRNA. Oncogenesis, 2020, 9(9): 81

[42] Zhang C, Zhi WI, Lu H, et al. Hypoxia- inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5- mediated modulation of RNA methylation in breast cancer cells. Oncotarget, 2016, 7(40): 64527- 64542

[43] Chao Y, Shang J, Ji W. ALKBH5- m6A- FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. Biochem Biophys Res Commun, 2020, 521(2): 499- 506

[44] Wang S, Wang Y, Zhang Z, et al. Long non- coding RNA NRON promotes tumor proliferation by regulating ALKBH5 and nanog in gastric cancer. J Cancer, 2021, 12(22): 6861- 6872

[45] Zhang J, Guo S, Piao HY, et al. ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the IncRNA NEAT1. J Physiol Biochem, 2019, 75(3): 379- 389

[46] Qu S, Jin L, Huang H, et al. A positive- feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis. BMC Cancer, 2021, 21(1): 686

[47] Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J Hematol Oncol, 2022, 15(1): 8

[48] Fukumoto T, Zhu H, Nacarelli T, et al. N6- methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res, 2019, 79(11): 2812- 2820

[49] Gawlik- rzemieniewska N, Bednarek I. The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells. Cancer Biol Ther, 2016, 17(1): 1- 10

[50] Wong OGW, Cheung ANY. Stem cell transcription factor NANOG in cancers—is eternal youth a curse? Expert Opin Therapeutic Targets, 2016, 20(4): 407- 417

[51] Ding C, Yi X, Chen X, et al. Warburg effect- promoted exosomal circ_0072083 releasing up- regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res, 2021, 40(1): 164

[52] Liu B, Zhou J, Wang C, et al. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5- mediated epigenetic regulation in glioblastoma. Cell Death Dis, 2020, 11(5): 384

[53] He Y, Hu H, Wang Y, et al. ALKBH5 inhibits pancreatic cancer motility by decreasing long non- coding RNA KCNK15- AS1 methylation. Cell Physiol Biochem, 2018, 48(2): 838- 846

[54] Tang B, Yang Y, Kang M, et al. m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF- 1 RNA methylation and mediating Wnt signaling. Mol Cancer, 2020, 19(1): 3

[55] He Y, Yue HQ, Cheng Y, et al. ALKBH5- mediated m6A demethylation of KCNK15- AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis, 2021, 12(12): 1121

[56] Yu H, Yang X, Tang J, et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A- CK2α- mediated glycolysis. Mol Ther Nucleic Acids, 2021, 23: 27- 41

[57] Jin H, Ying X, Que B, et al. N6- methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine, 2019, 47: 195- 207

引用本文

袁敏,周志刚杨萍陈灵瑶侯琳翁若兰涂剑. m6A去甲基化酶ALKBH5——新的原癌基因 [J]. 生命的化学. 2022; 42; (09). 1722 - 1728.

文献评论

相关学者

相关机构